Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.85 |
| ▸ | MMP9 | P14780 | 2/20 | 0.84 |
| ▸ | MMP3 | P08254 | 1/20 | 0.74 |
| ▸ | MMP7 | P09237 | 1/20 | 0.74 |
| ▸ | MMP10 | P09238 | 1/20 | 0.74 |
| ▸ | MMP8 | P22894 | 1/20 | 0.74 |
| ▸ | MMP12 | P39900 | 1/20 | 0.74 |
| ▸ | MMP13 | P45452 | 1/20 | 0.74 |
| ▸ | MMP14 | P50281 | 1/20 | 0.74 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5898015 | 0.96 | MMP2 (0.78) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL5897854 | 0.93 | MMP2 (0.89) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL7542099 | 0.93 | MMP2 (0.89) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL5898139 | 0.93 | MMP2 (0.89) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL5897938 | 0.93 | MMP2 (0.89) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL7542072 | 0.93 | MMP2 (0.89) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL7542064 | 0.93 | MMP2 (0.89) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL5898183 | 0.93 | MMP2 (0.89) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL7435467 | 0.92 | MMP2 (1.00) | MMP2MMP9MMP3MMP7MMP10 | |
| SCHEMBL5898234 | 0.92 | MMP2 (1.00) | MMP2MMP9MMP3MMP7MMP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | LU ZHONGHUI (US) | 2004-08-19 | — | — | US | claimed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | claimed |
| EP-1263755-A2 | CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | claimed |
| WO-2001070673-A2 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | LU ZHONGHUI (US) | 2004-08-19 | — | — | US | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | MMP2 8/4885MMP9 4/4885MMP3 27/4885 |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | MMP2 8/4885MMP9 4/4885MMP3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.